Primary myelofibrosis characterized by bone marrow hypercellularity and the presence of atypical megakaryocytes. There is no increase in the percentage of myeloblasts and no significant increase in re...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding cellular phase chronic idiopathic myelofibrosis is limited due to its rarity and the complexity of its clinical features. As this condition affects a small population, systematic clinical studies have been scarce, which hampers comprehensive understanding and documentation.
To navigate your care effectively, consider consulting a hematologist with expertise in myeloproliferative neoplasms. Additionally, you may explore clinical trials that could provide access to emerging therapies. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer guidance. Engaging in clinical trials may also provide insights into the condition's progression and treatment options.
There are several orphan drugs designated for this condition, including momelotinib and ruxolitinib phosphate, which are FDA-approved. Additionally, there are multiple drugs in development, such as bomedemstat and luspatercept. Currently, there are 17 active clinical trials exploring various treatment options. You can find more information about these trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=cellular%20phase%20chronic%20idiopathic%20myelofibrosis.
Actionable guidance for navigating care for cellular phase chronic idiopathic myelofibrosis
To navigate your care effectively, consider consulting a hematologist with expertise in myeloproliferative neoplasms. Additionally, you may explore clinical trials that could provide access to emerging therapies. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer guidance. Engaging in clinical trials may also provide insights into the condition's progression and treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding cellular phase chronic idiopathic myelofibrosis is limited due to its rarity and the complexity of its clinical features. As this condition affects a small population, systematic clinical studies have been scarce, which hampers comprehensive understanding and documentation.
To navigate your care effectively, consider consulting a hematologist with expertise in myeloproliferative neoplasms. Additionally, you may explore clinical trials that could provide access to emerging therapies. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer guidance. Engaging in clinical trials may also provide insights into the condition's progression and treatment options.
There are several orphan drugs designated for this condition, including momelotinib and ruxolitinib phosphate, which are FDA-approved. Additionally, there are multiple drugs in development, such as bomedemstat and luspatercept. Currently, there are 17 active clinical trials exploring various treatment options. You can find more information about these trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=cellular%20phase%20chronic%20idiopathic%20myelofibrosis.
Actionable guidance for navigating care for cellular phase chronic idiopathic myelofibrosis
To navigate your care effectively, consider consulting a hematologist with expertise in myeloproliferative neoplasms. Additionally, you may explore clinical trials that could provide access to emerging therapies. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer guidance. Engaging in clinical trials may also provide insights into the condition's progression and treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding cellular phase chronic idiopathic myelofibrosis is limited due to its rarity and the complexity of its clinical features. As this condition affects a small population, systematic clinical studies have been scarce, which hampers comprehensive understanding and documentation.
To navigate your care effectively, consider consulting a hematologist with expertise in myeloproliferative neoplasms. Additionally, you may explore clinical trials that could provide access to emerging therapies. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer guidance. Engaging in clinical trials may also provide insights into the condition's progression and treatment options.
There are several orphan drugs designated for this condition, including momelotinib and ruxolitinib phosphate, which are FDA-approved. Additionally, there are multiple drugs in development, such as bomedemstat and luspatercept. Currently, there are 17 active clinical trials exploring various treatment options. You can find more information about these trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=cellular%20phase%20chronic%20idiopathic%20myelofibrosis.
Actionable guidance for navigating care for cellular phase chronic idiopathic myelofibrosis
To navigate your care effectively, consider consulting a hematologist with expertise in myeloproliferative neoplasms. Additionally, you may explore clinical trials that could provide access to emerging therapies. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer guidance. Engaging in clinical trials may also provide insights into the condition's progression and treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.